CDIO Cardio Diagnostics Holdings, Inc. logo

CDIO Cardio Diagnostics Holdings, Inc.

Healthcare
$1.61+6.62%ClosedMarket Cap: $3.3M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

PEG

P/B

0.51

P/S

201.25

EV/EBITDA

0.51

DCF Value

$2.29

FCF Yield

-182.7%

Div Yield

0.0%

Margins & Returns

Gross Margin

-471.4%

Operating Margin

-40074.6%

Net Margin

-40152.5%

ROE

-78.8%

ROA

-69.6%

ROIC

-70.3%

Financials

View All
PeriodRevenueNet IncomeEPS
Q1 null$2.7K$-1.8M$
Q4 null$3.6K$-1.5M$
FY null$14.8K$-6.5M$
Q3 null$2.9K$-1.7M$

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$—

Target (Median)

$—

Target Range

$— - $—

0 Strong Buy1 Buy0 Hold0 Sell0 Strong Sell

Trading Activity

Insider Trades

View All
Intrater Jamesdirector
SellThu Apr 02
Fung Peter Kdirector
SellThu Apr 02
Burton Paul Frederickdirector
SellThu Apr 02
Betts Wendy Jdirector
SellThu Apr 02
Intrater Jamesdirector
SellTue Jan 06

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

US

Exchange

Beta

2.26

Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease risk assessment test. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is based in Chicago, Illinois.

Peers